Grufity logoGrufity logo

URGN

8.32USD+0.73(+9.62%)Delayedas of 28 Nov 2022, 01:28 pm

Urogen Pharma Ltd

Market Summary

USD8.32+0.73Delayedas of 28 Nov 2022, 01:28 pm
9.62%

URGN Stock Price

RSI Chart

Valuation

Market Cap

272.0M

Price/Earnings

-2.39

Price/Sales

4.71

Price/Cashflow

-3.14

MarketCap/EBT

-2.42

Price/Sales

Profitability

Operating Margin

89.25%

EBT Margin

-194.57%

Return on Equity

-1.4K%

Return on Assets

-77.83%

Fundamentals

Revenue

Revenue (TTM)

62.4M

Revenue Y/Y

27.41%

Revenue Q/Q

22.41%

Earnings

Earnings (TTM)

-109.4M

Earnings Y/Y

14.5%

Earnings Q/Q

3.22%

Price Action

52 Week Range

4.8512.63
(Low)(High)

Last 7 days

-9.5%

Last 30 days

-34.9%

Last 90 days

-3.2%

Trailing 12 Months

-40.5%

Financial Health

Current Ratio

7.74

Investor Care

Shares Dilution (1Y)

2.99%

Peers (Alternatives to Urogen Pharma)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
4.66% 39.76%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
2.35% -50.22%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
0.31% 13.58%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
0.58% 68.05%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
5.82% 12.67%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
17.73% 33.91%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
0.23% 41.48%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-5.94% -0.54%
-18.85
63.29
26.15% -23.38%
3.8B
-
41.63% -30.16%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
-10.09% -56.96%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-10.63% -53.96%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
18.84% 129.95%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
-5.86% -21.13%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
28.14% -69.87%
-1.4
4.57
-43.57% -69.06%
16.0M
-
-12.01% -87.39%
-0.46
19.11
-77.61% 5.14%

Financials for Urogen Pharma

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue8.2%6258544840
Gross Profit7.7%5551484336
  S&GA Expenses-3.0%8385878888
  R&D Expenses2.3%5250504847
Earnings Before Taxes4.5%-107.16-112.25-111.50-109.37-109.21
Net Income3.9%-109.37-113.75-113.28-110.82-112.89
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-12.1%128146166120135
  Current Assets-12.9%122140161114125
    Cash Equivalents-64.4%29811054455
  Inventory-3.7%55554
  Net PPE-5.4%22222
Liabilities2.5%192187183111103
  Current Liabilities5.3%1918192220
    LT Debt, Non Current0.9%727171--
Shareholder's Equity-54.7%-63.29-40.91832-
  Retained Earnings-4.9%-548.23-522.40-495.70-467.30-438.90
  Additional Paid-In Capital0.7%485481479476470
Accumulated Depreciation8.9%33222
Shares Outstanding1.2%2323232322
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations1.0%-85,877.00-86,741.00-81,487.00-84,892.00-86,064.00
  Share Based Compensation-18.5%13,56916,64419,86723,11324,282
Cashflow From Investing-138.9%-12,923.0033,2302,6414,06944,409
Cashflow From Financing1.8%71,73470,465143,05772,31972,429

Risks

What is the probability of a big loss on URGN?

89.6%


Probability that Urogen Pharma stock will be more than 20% underwater in next one year

88.1%


Probability that Urogen Pharma stock will be more than 30% underwater in next one year.

72.3%


Probability that Urogen Pharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does URGN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Urogen Pharma was unfortunately bought at previous high price.

Returns

Cumulative Returns on URGN

-28.6%


5-Year Cumulative Returns

-37.3%


3-Year Cumulative Returns

What are the long-term rolling returns for URGN?

FIve years rolling returns for Urogen Pharma.

Which funds bought or sold URGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-15
ALGERT GLOBAL LLC
SOLD OFF
-100
-85,000
-
-%
2022-11-15
Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD
UNCHANGED
-
2,000
179,000
0.04%
2022-11-15
Coastal Bridge Advisors, LLC
UNCHANGED
-
5,000
308,000
0.08%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
REDUCED
-82.44
-51,006
11,074
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
1,000
12,000
-%
2022-11-15
STATE STREET CORP
REDUCED
-24.36
-258,000
853,000
-%
2022-11-15
Balyasny Asset Management LLC
NEW
-
99,000
99,000
-%
2022-11-14
RENAISSANCE TECHNOLOGIES LLC
-
-
2,000
359,000
-%
2022-11-14
Qube Research & Technologies Ltd
REDUCED
-11.07
-11,000
111,000
-%

1–10 of 46

Latest Funds Activity

Are funds buying URGN calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own URGN

Urogen Pharma News

MarketBeat

FY2022 EPS Estimates for UroGen Pharma Ltd. Lowered by Analyst (NASDAQ:URGN).12 hours ago

GuruFocus.com

URGN Fair Value

Recent SEC filings of Urogen Pharma

View All Filings
Date Filed Form Type Document
Nov 16, 2022
S-3/A
S-3/A
Nov 15, 2022
S-3
S-3
Nov 10, 2022
10-Q
Quarterly Report
Nov 10, 2022
8-K
Current Report
Nov 09, 2022
3
Insider Trading
Nov 09, 2022
4
Insider Trading
Nov 09, 2022
8-K
Current Report
Nov 02, 2022
4
Insider Trading
Oct 25, 2022
4
Insider Trading
Oct 21, 2022
8-K
Current Report

Latest Insider Trading transactions for URGN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-31
Schoenberg Mark
SOLD
-3,057.3
11.85
-258
Chief Medical Officer
2022-10-31
Schoenberg Mark
ACQUIRED
-
-
500
Chief Medical Officer
2022-10-21
Nussbaum Ran
ACQUIRED
285,114
5.94
47,999
-
2022-09-14
Belldegrun Arie
ACQUIRED
800,000
5
160,000
-
2022-08-31
Belldegrun Arie
ACQUIRED
16,205
5
3,241
-
2022-08-31
Smith Jason Drew
ACQUIRED
-
-
8,333
General Counsel
2022-08-31
Smith Jason Drew
SOLD
-25,999.3
7.21
-3,606
General Counsel
2022-08-01
Schoenberg Mark
SOLD
-2,022.79
7.81
-259
Chief Medical Officer
2022-07-31
Schoenberg Mark
ACQUIRED
-
-
500
Chief Medical Officer
2022-06-06
Nussbaum Ran
ACQUIRED
5,150
5
1,030
-

1–10 of 50

URGN Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue$ 16,097$ 11,351$ 46,265$ 31,868
Cost of revenue2,0201,2445,3913,568
Gross profit14,07710,10740,87428,300
Operating expenses:    
Research and development expenses13,09311,92338,42934,560
Selling, general and administrative expenses19,07121,62461,20466,117
Operating loss(18,087)(23,440)(58,759)(72,377)
Financing on prepaid forward obligation(4,819)(6,828)(16,478)(9,948)
Interest expense on long-term debt(2,694)0(5,215)0
Interest and other income, net47857604269
Loss before income taxes(25,122)(30,211)(79,848)(82,056)
Income tax expense(709)0(1,066)(312)
Net Loss(25,831)(30,211)(80,914)(82,368)
Statements of Comprehensive Loss    
Net loss(25,831)(30,211)(80,914)(82,368)
Other comprehensive (loss)    
Unrealized (loss) on investments(99)(41)(130)(267)
Comprehensive Loss$ (25,930)$ (30,252)$ (81,044)$ (82,635)
Net loss per ordinary share - basic and diluted (in dollars per share)$ (1.13)$ (1.35)$ (3.56)$ (3.69)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)22,798,26322,380,59822,711,68622,318,589

URGN Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 28,686$ 44,360
Marketable securities67,22544,779
Restricted cash8121,226
Accounts receivable9,42911,717
Inventories4,8624,832
Prepaid expenses and other current assets10,5807,476
Total current assets121,594114,390
Non-current assets:  
Property and equipment, net1,5191,967
Restricted deposit223223
Right of use assets2,6661,180
Marketable securities0675
Other non-current assets2,4711,311
Total Assets128,473119,746
Current liabilities:  
Accounts payable and accrued expenses9,35612,102
Employee related accrued expenses6,6256,948
Other current liabilities3,0183,330
Total current liabilities:18,99922,380
Non-current liabilities:  
Prepaid forward obligation96,19285,713
Long-term debt71,8700
Long-term lease liabilities1,856398
Uncertain tax positions liability2,8422,842
Total Liabilities191,759111,333
Commitments and Contingencies (Note 18)
Shareholders' Equity (Deficit):  
Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at September 30, 2022 and December 31, 2021; 23,011,324 and 22,462,995 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively6361
Additional paid-in capital485,041475,698
Accumulated deficit(548,235)(467,321)
Accumulated other comprehensive loss(155)(25)
Total Shareholders' Equity (Deficit)(63,286)8,413
Total Liabilities and Shareholders' Equity (Deficit)$ 128,473$ 119,746